CFO Mark Stolper told attendees at KeyBanc’s Healthcare Forum that the company exited 2025 with what he described as “unprecedented” momentum in imaging volumes, while its digital health business ...
Telix Pharmaceuticals (ASX:TLX) has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer. The company reported that Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results